Jay S. Skyler, MD, MACP, FRCP

Jay S. Skyler, is a Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology Diabetes & Metabolism, Department of Medicine, University of Miami Leonard M. Miller School of Medicine, and is the Deputy Director for Clinical Research and Academic Programs at the University’s Diabetes Research Institute.  He also is an Adjunct Professor of Pediatrics at the Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver. From 1993 until 2015, he was Chairman of the NIH (NIDDK)-sponsored Diabetes Prevention Trial - Type 1 (DPT-1) and its successor Type 1 Diabetes TrialNet, a nationwide (and global) network conducting clinical trials to interdict type 1 diabetes. During his tenure, 14 clinical intervention trials were initiated. Currently, he is Chair of the Strategy Advisory Group for INNODIA, a European consortium of academic and industry groups developing innovative approaches towards understanding and arresting type 1 diabetes. 

Dr. Skyler is a graduate of Pennsylvania State University and Jefferson Medical College and did his postgraduate training in Internal Medicine and in Endocrinology & Metabolism at Duke University Medical Center where he was also on the faculty. After two years at the Hypertension-Endocrine Branch of the National Heart and Lung Institute, National Institutes of Health, he joined the University of Miami in 1976.

Dr. Skyler has been the recipient of multiple honors, including Banting Medal for Service from the American Diabetes Association, First George Eisenbarth Memorial Lecturer for the Immunology of Diabetes Society, Distinction in Endocrinology Award from the American College of Endocrinology, Mary Tyler Moore/S. Robert Levine Award for Distinction in Clinical Research from the Juvenile Diabetes Research Foundation, Alumni Achievement Award from Jefferson Medical College, Josiah K. Lilly Award from the American Diabetes Association, Distinguished Faculty Scholar Award from the Faculty Senate of the University of Miami, Master of the American College of Physicians, Fellow of the Royal College of Physicians (FRCP) of the United Kingdom.

Dr. Skyler served as 50^th national President of the American Diabetes Association, Chair of the Council of Subspecialty Societies (of the American College of Physicians), President of the Southern Society for Clinical Investigation, Vice-President of the International Diabetes Federation, and President of the International Diabetes Immunotherapy Group.

He was founding Editor-in-Chief of the ADA professional journal, Diabetes Care, founding Scientific Editor of International Diabetes Monitor, and Senior Editor of Diabetes Technology & Therapeutics. Dr. Skyler has been author, editor, or co-editor of 21 books or monographs, and has written over 550 articles, book chapters, or editorials. He also has edited 14 special journal symposia. 

Dr. Skyler is a scientific advisor to the pharmaceutical, biotechnology, and medical equipment industries, advising over 250 companies. He chaired the Scientific Advisory Board and served on the Board of Directors of MiniMed Inc. (NASDAQ - MNMD), developer of a novel insulin pump and the first continuous glucose monitoring system (company acquired by Medtronic in 2001 for $3.4 billion). He was on the Board of Directors of Amylin Pharmaceuticals, Inc. (NASDAQ – AMLN) from 1999 until that company was acquired by Bristol-Myers-Squibb and AstraZeneca in 2012 (for $7 billion), and during his tenure Amylin had three first-in-class products approved. From 2002 to 2023, he was on the Board of Directors of Dexcom, Inc., which had a successful IPO in April 2005 had its first continuous glucose sensor approved in 2006, and its seventh-generation sensor approved in 2022, and at the time he stepped off the Board in May 2023, Dexcom had a market cap of $46 billion. He is a member of the Board of Directors of Applied Therapeutics, which had a successful IPO in May 2019.  He has also served on the Board of Directors of several private companies.